Drawing on his work in cancer research, Dr Sergey Tumanov is spearheading a groundbreaking study at the Heart Research Institute’s Fluxomics Centre devoted to CVD – the first of its kind in Australia.
“We need to understand the unique cellular changes in each person’s CVD; this effectively creates a ‘chemical fingerprint’ that predicts your likelihood of developing CVD, and developing the most effective treatments for you,” Dr Tumanov explains.
“While current technologies only provide static ‘snapshots’ of a cell at any given time, fluxomics is an innovative research field that shows changes to cells over time. This is particularly important to understanding progressive diseases affecting the heart and blood vessels.”
At the heart of the Fluxomics Centre is a state-of-the-art machine able to detect the building blocks that make up our cells: a mass spectrometer.
To make this research a reality, your support is vital. Will you donate to help fund a mass spectrometer that will help give every heart the exact treatment it needs?
Using this mass spectrometer alongside other high-tech lab equipment, Dr Tumanov and his team aim to unlock some of the key mysteries of cardiovascular research. Why do people leading healthy lifestyles get CVD? Why do current treatments work well for some, but not others? Why do women and men develop heart disease in different ways?